Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | CFO | December 10, 2021 | December 14, 2021 |
| Definium Therapeutics, Inc.MNMD · Entity 3884 | Chief Financial Officer | March 25, 2024 | March 26, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date December 10, 2021 · Filed December 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,883 |
Reported balance
After 2021-12-10 transaction · row 1
1 source rowRow 1 · 2021-12-10 · Purchase · Acquired 2,231 · Balance 3,883 F1: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan.
Definium Therapeutics, Inc.
Report date March 25, 2024 · Filed March 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 211,057 |
Reported balance
After 2024-03-25 transaction · row 1
1 source rowRow 1 · 2024-03-25 · Tax withholding · Disposed 5,560 · Balance 211,057 F1: Represents the number of Common Shares withheld to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, as permitted by the Issuer's Performance and Restricted Share Unit Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of Common Shares withheld to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, as permitted by the Issuer's Performance and Restricted Share Unit Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2024 Filed Mar 26, 2024 21:16 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | Tax withholdingCommon Shares | 5,560 | $9.78 | $54,376.80 |
DisclosureSEC source: 0000950170-24-036578 · ownership.xml · nonDerivative · entry 1 Greenway Schond L. · CIK 0001848205 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,057 F1 · shares: Represents the number of Common Shares withheld to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, as permitted by the Issuer's Performance and Restricted Share Unit Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:45 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0000950170-24-023204 · ownership.xml · derivative · entry 1 Greenway Schond L. · CIK 0001848205 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 150,000 shares Expires 2034-02-26 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in 48 equal monthly installments, with the first installment vesting on March 27, 2024, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date. Read SEC document |
| December 26, 2023 Filed Dec 26, 2023 21:44 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 5,652 | $3.63 | $20,516.76 |
DisclosureSEC source: 0000950170-23-073063 · ownership.xml · nonDerivative · entry 1 Greenway Schond L. · CIK 0001848205 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,617 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2023 at prices ranging from $3.60 to $3.67 US Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2023 Filed Sep 26, 2023 01:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 3,854 | $3.58 | $13,797.32 |
DisclosureSEC source: 0000950170-23-049777 · ownership.xml · nonDerivative · entry 2 Greenway Schond L. · CIK 0001848205 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,269 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F3 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2023 at prices ranging from $3.57 to $3.60 US Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2023 Filed Sep 26, 2023 01:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 1,908 | $3.57 | $6,811.56 |
DisclosureSEC source: 0000950170-23-049777 · ownership.xml · nonDerivative · entry 1 Greenway Schond L. · CIK 0001848205 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,123 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F2 · price: The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on September 25, 2023. These shares were sold in multiple transactions on September 25, 2023 at prices ranging from $4.78 to $4.84 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 00:01 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 20,000 | $3.80 | $76,000.00 |
DisclosureSEC source: 0000950170-23-044853 · ownership.xml · nonDerivative · entry 1 Greenway Schond L. · CIK 0001848205 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,031 F1 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on August 25, 2023 at prices ranging from $3.76 to $3.87. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 27, 2023 Filed Jun 27, 2023 22:53 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 3,941 | $3.21 | $12,650.61 |
DisclosureSEC source: 0000950170-23-030242 · ownership.xml · nonDerivative · entry 2 Greenway Schond L. · CIK 0001848205 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,031 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F3 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 27, 2023 at prices ranging from $3.20 to $3.23 US Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 27, 2023 Filed Jun 27, 2023 22:53 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 7,694 | $3.19 | $24,543.86 |
DisclosureSEC source: 0000950170-23-030242 · ownership.xml · nonDerivative · entry 1 Greenway Schond L. · CIK 0001848205 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,972 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections. F2 · price: The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on June 27, 2023. These shares were sold in multiple transactions on June 27, 2023 at prices ranging from $4.20 to $4.23 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 14, 2023 Filed Mar 17, 2023 22:38 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantCommon Shares | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019890 · doc4.xml · nonDerivative · entry 1 Greenway Schond L. · CIK 0001848205 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,445,000 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 14, 2023, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| March 14, 2023 Filed Apr 24, 2023 23:34 UTC Amendment | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantCommon Shares | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025476 · doc4a.xml · nonDerivative · entry 1 Greenway Schond L. · CIK 0001848205 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,666 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 14, 2023, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| May 23, 2022 Filed May 23, 2022 21:53 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 1,650,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001209191-22-031402 · doc4.xml · derivative · entry 2 Greenway Schond L. · CIK 0001848205 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650,000 Underlying: Subordinate Voting Shares · 1,650,000 shares Expires 2027-05-22 F2 · derivative.exercise_price: The option grant has an exercise price of $0.91 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable, with 25% vesting on May 23, 2023, and 1/36th of the remaining shares vesting monthly thereafter over 36 months, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date. Read SEC document |
| May 23, 2022 Filed May 23, 2022 21:53 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantSubordinate Voting Shares | 1,270,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031402 · doc4.xml · nonDerivative · entry 1 Greenway Schond L. · CIK 0001848205 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,270,000 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. Of these RSUs, 25% shall vest on May 23, 2023 with 1/12th of the remaining shares vesting each quarter thereafter over 12 quarters, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| May 23, 2022 Filed Jun 3, 2022 20:06 UTC Amendment | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 1,650,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-22-033984 · doc4a.xml · derivative · entry 2 Greenway Schond L. · CIK 0001848205 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650,000 Underlying: Subordinate Voting Shares · 1,650,000 shares Expires 2027-05-22 F2 · derivative.exercise_price: The option grant has an exercise price of $1.00 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable, with 25% vesting on May 23, 2023, and 1/36th of the remaining shares vesting monthly thereafter over 36 months, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date. Read SEC document |
| May 23, 2022 Filed Jun 3, 2022 20:06 UTC Amendment | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantSubordinate Voting Shares | 1,270,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-033984 · doc4a.xml · nonDerivative · entry 1 Greenway Schond L. · CIK 0001848205 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,270,000 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. Of these RSUs, 25% shall vest on May 23, 2023 with 1/12th of the remaining shares vesting each quarter thereafter over 12 quarters, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 22:13 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 2,231 | $1.57 | $3,502.67 |
DisclosureSEC source: 0001879785-21-000035 · edgar.xml · nonDerivative · entry 1 Greenway Schond L. · CIK 0001848205 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,883 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:03 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 652 | $2.68 | $1,747.36 |
DisclosureSEC source: 0001192482-21-000500 · edgar.xml · nonDerivative · entry 1 Greenway Schond L. · CIK 0001848205 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,652 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| March 01, 2021 Filed Mar 1, 2021 22:14 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001192482-21-000194 · edgar.xml · derivative · entry 1 Greenway Schond L. · CIK 0001848205 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-03-01 F1 · derivative.exercise_date: The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the following 36 months, subject to the reporting person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.